Understanding Prostate Cancer and treatment options A Guidebook for Patients & Caregivers Contents 3 4 7 10 13 24 36 54 57 61 64 70 78 Introduction The Prostate Gland Prostate Cancer Risk Factors Identification and Screening for Prostate Cancer Stages of Prostate Cancer Treatment of Prostate Cancer Treatment Options by Stage Prognosis Living with Prostate Cancer Additional Information About Prostate Cancer Glossary References Introduction Introduction A diagnosis of prostate cancer can raise many questions and fears. You, your family, and others close to you may not know what prostate cancer is or how it can be treated. As you learn about prostate cancer and its treatment, these concerns may be eased. No booklet can provide all the information you need to decide if a treatment is right for you. This booklet does not take the place of careful discussions with your doctor. By working together, you and your doctor will plan the treatment that is best for you. This booklet is designed for you and those close to you. To help you understand and cope with the diagnosis of prostate cancer, this booklet: In addition to this booklet, several helpful sources of information about prostate cancer are available at local libraries and from cancer societies and support groups. A list of support groups and resources is also provided. • Explains how prostate cancer develops and describes its various stages; • Provides information about how prostate cancer is treated; • Discusses the effects that prostate cancer may have on your life and offers some ways to cope. Introduction 3 The Prostate Gland The Prostate Gland Function..................................................................4 Anatomy............................................................4 Changes in the Prostate with Age.....................5 Function Anatomy The prostate gland is a muscular, walnut-sized gland that surrounds part of the urethra, the tube that transports urine and sperm out of the body. A gland is a group of cells that secretes chemicals that act on or control the activity of other cells or organs. The prostate is a gland in the male reproductive system located underneath the bladder and in front of the rectum. The main function of the prostate is to produce semen, the milky fluid that transports sperm. Sperm is produced in the testicles, which also produce the main male hormone, testosterone. Testosterone stimulates the growth and function of the prostate during puberty, as well as the production of prostatic fluid for semen. During sexual climax (orgasm), the muscles of the prostate contract to push the semen through the urethra and out through the penis. 4 The Prostate Gland Figure 1. Anatomy of the male reproductive and urinary systems, showing the prostate, testicles, bladder, and other organs. Photo courtesy of the National Cancer Institute. Physicians refer to the left and right lobes of the prostate gland, particularly when discussing what they can actually feel or palpate during a digital rectal examination. Changes in the Prostate with Age At birth, the prostate has a system of ducts that forms a large part of the gland. During the first 12–14 years of life, there are very few anatomical changes. At puberty, which generally occurs between the ages of 14 and 18 years, the prostate gland begins to mature under the influence of hormones. During this period, its size increases more than twofold. This allows the prostate gland to function in the reproductive process. The Prostate Gland 5 The Prostate Gland It may enlarge as a man gets older, a process called hypertrophy or hyperplasia. As a result of an enlarged prostate gland, a man may find it difficult to urinate normally because the gland surrounds the urethra. Because of its close proximity to the rectum, the prostate gland is relatively easy to examine using what is called a digital rectal examination or DRE, discussed later in this brochure, which is performed to determine the size of the prostate gland. As shown in Figure 2, a normal prostate allows the flow of urine from the bladder. An enlarged prostate presses on the bladder and urethra, and blocks the flow of urine. When a man is between the ages of 30 and 40, the glandular portion of the prostate begins to enlarge. After that, the size of the prostate remains virtually the same until 45–50 years of age, when the prostate gland begins to change in ways that make it less functional (called prostatic involution). After 45–50 years of age, in some men, the prostate tends to develop what is called benign prostatic hyperplasia or BPH. While it can have symptoms similar to those of prostate cancer, BPH is not prostate cancer. Figure 2: Normal prostate and benign prostatic hyperplasia (BPH). Photo courtesy of the National Cancer Institute. 6 The Prostate Gland Prostate Cancer Prostate Cancer Who Gets Prostate Cancer?..................................................................8 New Cases per Year (Incidence).....................................................8 Number of Cases at Any One Time (Prevalence)..........................9 Prostate cancer occurs when cells in the prostate become abnormal and grow without control. Metastatic prostate cancer, otherwise known as stage IV prostate cancer, is the most advanced stage of prostate cancer and means that the cancer has spread from its original location. In metastatic prostate cancer, prostate cancer cells break away from the main tumor and travel, or metastasize, through the blood or another body fluid, called lymph, to other parts of the body. The most common places to which these tumor cells travel are the bones. Prostate Cancer Prostate cancer is a disease in which cancer cells form in the tissues of the prostate. Figure 3. Prostate cancer as shown on a colored computed tomography (CT) scan Prostate Cancer 7 Figure 3 is a colored CT scan representing a cross-section through the pelvis. This CT scan shows an enlarged prostate gland with cancer. At center is the prostate (green) seen between the bones of the pelvis (red). At lower center, next to the prostate, is the rectum (light blue). Above the prostate is the bladder (yellow) which has been indented by the enlarged prostate. Who Gets Prostate Cancer? Prostate cancer is a major health care challenge. It is the second most common cancer in men (behind skin cancer) and the second leading cause of cancer death (behind lung cancer). It is estimated that 241,740 men will be diagnosed with and 28,170 men will die of cancer of the prostate in 2012. 8 Prostate Cancer New Cases Per Year (Incidence) US government data provide insights into factors such as age, race, and survival by stage of cancer. Almost 10% of men with prostate cancer receive a diagnosis between the ages of 45 and 54, about 68% are diagnosed between the ages of 45 and 75, and about 20% above the age of 75. Above the age of 75, men are often dying of other causes before prostate cancer is detected. Table 1: Incidence Rates by Race, 2005-2009 Race/Ethnicity Number per 100,000 Men All Races 154.8 White 146.9 Black 236.0 85.4 American Indian/Alaska Native 78.4 Hispanic 125.9 On January 1, 2009, in the United States there were approximately 2,496,784 men alive who had a history of cancer of the prostate. This includes any person alive on January 1, 2009, who had been diagnosed with cancer of the prostate at a particular point prior to January 1, 2009, and includes persons with active disease and those who had been cured of their disease. Prostate Cancer Asian/Pacific Islander Number of Cases at Any One Time (Prevalence) Another way of understanding how common prostate cancer really is, is reflected in the statement that 1 out of every 6 men born today will be diagnosed with cancer of the prostate at some time during his lifetime. Prostate Cancer 9 Risk Factors Although the exact cause of prostate cancer has not been identified, it is believed to be related to a variety of factors such as age, race, testosterone and other androgens (male hormones), heredity and certain lifestyle factors. Risk Factors Aging.................................................................10 Obesity and Diet................................................11 Hormones..........................................................11 Race and Ethnicity............................................12 Heredity.............................................................12 Aging As mentioned previously, prostate cancer is a disease of older men. The rates of prostate cancer diagnosis and death increase with age. Although screening men with the prostate-specific antigen (PSA) test has helped to identify patients earlier in life than was possible a generation ago, death from prostate cancer is still largely confined to men who are at least 70 years of age—with some exceptions, of course. As people are 10 Risk Factors living longer due to better nutrition and health practices, prostate cancer has become an even more important health care consideration, both from the standpoint of its effect on patients’ lives, as well as on the cost of care. This has generated a sense of urgency among physicians to manage prostate cancer more effectively and to be able to provide therapy to patients who need it. Obesity and Diet Factors such as diet, caloric intake, and obesity have been implicated in the development of prostate cancer. Obesity, defined as body mass index (BMI) above 30, is characterized by an excess of what is called “white fat” or “white adipose tissue.” Obesity has been associated with progression of several types of cancer, including prostate cancer. • Obese patients with prostate cancer are more likely to develop a recurrence following removal of the prostate gland (radical prostatectomy) or radiation therapy for disease that is confined to the prostate gland. Hormones Androgens are important to the normal growth and development of the prostate gland as well as to the growth of prostate cancer. Some patients can be treated with drugs that decrease the availability of androgens such as testosterone. However, for reasons not completely understood, some prostate cancers become able to survive and grow with little or no androgen stimulation, requiring different approaches to treatment. Risk Factors 11 Risk Factors • It is believed that genetic traits associated with both obesity and cancers are influenced by lifestyle components such as diet and physical activity. • Prostate cancer can also be accelerated in obese patients independent of their physical activity and type of diet, suggesting that white fat may have a direct effect on cancer progression. Race and Ethnicity Heredity African Americans have a higher frequency of death from prostate cancer than Caucasian and Hispanic Americans, although the reasons are unclear. Chinese and Japanese Americans have a decreased frequency of prostate cancer, although it is higher than in Chinese and Japanese men who remain in their native countries. Men from northern Europe have a higher frequency of prostate cancer than men from southern Europe. There appears to be a familial tendency for prostate cancer, although it is not a direct genetic link to a specific gene or chromosome. In fact, no specific genetic abnormalities or profiles have been identified that would make genetic screening for prostate cancer feasible for early identification. Men carrying BRCA1/BRCA2 mutations—which are important in the development of breast and ovarian cancer in some women—have been shown to be at increased risk of developing prostate cancer, although the exact mechanisms are not known. 12 Risk Factors Possible Signs of Prostate Cancer The following symptoms may be caused by prostate cancer as well as by other conditions: • Weak or interrupted flow of urine; • Frequent urination (especially at night); • Trouble urinating; Identification and Screening for Prostate Cancer Possible Signs of Prostate Cancer.....................................13 Screening for Prostate Cancer ......................................14 To Screen or Not to Screen........................................14 More about Prostate Cancer Screening.....................15 Digital Rectal Exam (DRE)........................................16 Prostate-Specific Antigen (PSA) Test.......................17 More about PSA Testing............................................18 Diagnostic Tests................................................................19 Transrectal Ultrasound...............................................19 Biopsy..........................................................................20 Transrectal Biopsy.......................................................21 Transperineal Biopsy...................................................22 The Gleason Grading System..........................................22 • Pain or burning during urination; • Blood in the urine or semen; • Pain in the back, hips, or pelvis that doesn’t go away; • Painful ejaculation. Identification and Screening for Prostate Cancer 13 Identification and Screening for Prostate Cancer Identification and Screening for Prostate Cancer Screening for Prostate Cancer Whether screening for prostate cancer results in a decrease in rates of death due to the disease is the subject of much debate. The screening tests currently available include digital rectal examination (DRE) and prostate-specific antigen (PSA) testing. Most cancers detected by DRE alone are advanced, so most physicians currently use a combination of DRE and PSA testing. To Screen or Not to Screen For a variety of reasons there has been considerable discussion about the benefit of screening men at average risk of prostate cancer. 14 Identification and Screening for Prostate Cancer • Whether screening for prostate cancer results in a decrease in rates of death due to the disease is the subject of much debate • There is no reliable way to predict which cancers will be slow-growing and which will be aggressive • Prostate cancer tends to be a slow-growing disease, and some of the small tumors that are found by the PSA test may not be life-threatening; thus some men may undergo unnecessary treatment • Treatments for prostate cancer can lead to complications, such as impotence and urinary incontinence, which can affect men’s quality of life Identification and Screening for Prostate Cancer • However, some prostate cancers can grow and spread quickly and are termed aggressive • In such cases, PSA screening may help find prostate cancer early, while it is easier to treat More about Prostate Cancer Screening PSA testing increases the detection rate of prostate cancers compared with DRE. Approximately 2–2.5% of men older than 50 years of age will be found to have prostate cancer using PSA testing, compared with a rate of approximately 1.5% using DRE alone. Multiplying the difference in these percentages by the actual number of patients that are screened suggests that in order to diagnose the most true cases of prostate cancer, using both tests is highly advisable. prostatic hyperplasia and those with prostate cancers. Thus PSA screening will identify a considerable number of men with high PSA but without prostate cancer. The most frequent noncancerous causes of elevated PSA include prostatitis (inflammation of the prostate) and benign prostatic hyperplasia (BPH). PSA-detected cancers are more likely to be localized compared with those detected by DRE alone. On the other hand, screening for elevated PSA will not detect all prostate cancers. The Prostate Cancer Prevention Trial provided data demonstrating a significant risk of prostate cancer even in men with PSA less than 4.0 ng/mL. In fact, some men with a normal PSA result may have prostate cancer. Keep in mind that PSA is not specific for cancer, and there is considerable overlap of values between men with benign Identification and Screening for Prostate Cancer 15 Additional information about DRE, PSA, and several other tests used to assess the possibility of prostate cancer are provided below. Digital Rectal Exam (DRE) A digital rectal exam (DRE) is an exam in which the doctor or nurse inserts a lubricated, gloved finger into the rectum and feels the prostate for lumps or abnormal areas through the rectal wall. Figure 4: Digital rectal exam (DRE). Photo courtesy of the National Cancer Institute. 16 Identification and Screening for Prostate Cancer Identification and Screening for Prostate Cancer Prostate-Specific Antigen (PSA) Test As previously described, the PSA test measures the level of PSA in the blood. PSA is a substance made by the prostate that may be found in an increased amount in the blood of men who have prostate cancer. PSA levels may also be high in men who have an infection or inflammation of the prostate or BPH (an enlarged, but noncancerous, prostate). PSA is a protein produced primarily by cells, either benign or malignant, of the prostate gland. The serum level is typically low and correlates with the volume of both benign and malignant prostate tissue. Measurement of serum PSA is useful in detecting and staging prostate cancer, monitoring response to treatment, and detecting recurrence before it becomes clinically evident. • When used as a screening test, PSA levels are found to be elevated in up to 15% of men. • Up to 30% of men with intermediate degrees of elevation (4.1–10 ng/mL) will be found to have prostate cancer. • Between 50% and 70% of those with elevations >10 ng/mL will have prostate cancer. Patients with intermediate levels of PSA usually have localized and therefore potentially curable cancers. Approximately 20% of patients who undergo radical prostatectomy for localized prostate cancer have normal levels of PSA, meaning that a normal PSA level does not rule out prostate cancer. A rising PSA after therapy is usually consistent with progressive disease, either locally recurrent or metastatic. Identification and Screening for Prostate Cancer 17 More about PSA Testing Sometimes results of standard PSA testing suggest the need for more specialized PSA testing such as: • PSA velocity (PSAV): PSAV measures how fast PSA rises over time. Although PSA typically rises with age, in men who have prostate cancer, PSA levels can rise faster than normal • PSA doubling time is a measure of how long it takes for a man’s PSA level to double. • Percent free PSA (fPSA): There are 2 forms of PSA in the blood—PSA that circulates in an unbound or free form, and PSA that is bound to blood proteins. fPSA is the ratio of how much PSA circulates in the unbound form compared with the total PSA level. fPSA is lower in men who have prostate cancer compared with those who do not. • Complexed PSA (cPSA): This is a newer test that measures the amount of PSA that is bound to blood proteins. It is an alternative to the fPSA test 18 Identification and Screening for Prostate Cancer Identification and Screening for Prostate Cancer Diagnostic Tests Once prostate cancer is suspected based on screening tests, a number of other tests may be performed to establish or eliminate the diagnosis. These include transrectal ultrasound, transrectal biopsy, and transperineal biopsy. Transrectal Ultrasound During a transrectal ultrasound procedure, a probe about the size of a finger is inserted into the rectum to check the prostate. The probe bounces ultrasound waves off internal tissues or organs, creating echoes. The echoes form a sonogram picture of body tissues. Transrectal ultrasound may also be used during a biopsy procedure. Figure 5: Transrectal ultrasound. Photo courtesy of the National Cancer Institute. Identification and Screening for Prostate Cancer 19 As shown in Figure 5, an ultrasound probe is inserted into the rectum to check the prostate. The probe bounces sound waves off body tissues to make echoes that form a sonogram (computer picture) of the prostate. Transrectal ultrasound has primarily been used for the staging of prostate carcinomas, where tumors typically appear as areas without an echo (dark areas on the ultrasound). In addition, transrectal ultrasound-guided biopsy of the prostate is a more accurate way to evaluate suspicious lesions than digitally guided biopsy. Asymptomatic patients with cancers thought to be localized to the prostate on DRE and transrectal ultrasound and associated with modest elevations of PSA (i.e., <10 ng/ mL), may not need any further imaging. 20 Identification and Screening for Prostate Cancer Biopsy A biopsy involves the removal of cells or tissues to be viewed under a microscope by a pathologist. The pathologist checks the biopsy sample for cancer cells and to determine a Gleason score, which will be discussed in greater detail below. The Gleason score describes how likely it is that a tumor will spread. It ranges from 2-10, and the lower the number, the less likely the tumor is to spread. As described below, there are two types of biopsy procedures used to diagnose prostate cancer— transrectal biopsy and transperineal biopsy. Identification and Screening for Prostate Cancer Transrectal Biopsy A transrectal biopsy involves the removal of tissue from the prostate by inserting a thin needle through the rectum and into the prostate. This procedure is usually done using transrectal ultrasound to help guide the needle. A pathologist then views the removed tissue under a microscope to look for cancer cells. Transrectal ultrasound-guided biopsy is the standard method for detection of prostate cancer. Local anesthesia is routinely used and increases the tolerability of the procedure. The specimen preserves glandular structure and permits accurate grading. Prostate biopsy specimens are taken from the several different areas of the prostate gland in men who have an abnormal DRE or an elevated serum PSA, or both. A total of at least ten biopsies is associated with improved cancer detection and risk assessment of patients with newly diagnosed disease. Figure 6. Transrectal biopsy. Photo courtesy of the National Cancer Institute. As shown in Figure 6, an ultrasound probe is inserted into the rectum to show where the tumor is. Then a needle is inserted through the rectum into the prostate to remove tissue from the prostate. Identification and Screening for Prostate Cancer 21 Transperineal Biopsy The Gleason Grading System In a transperineal biopsy, tissue is removed from the prostate by inserting a thin needle through the skin between the scrotum and rectum and into the prostate. As in other biopsies, a pathologist then views the tissue under a microscope to look for cancer cells. A pathologist will examine the biopsy samples. If prostate cancer cells are found, he or she will classify them according to the Gleason system. From Epstein JI. Pathology of prostatic neoplasia. In: Walsh PC, eds. Campbell’s Urology. Philadelphia: WB Saunders; 2002 22 Identification and Screening for Prostate Cancer Identification and Screening for Prostate Cancer The Gleason score represents a composite classification based on a combination of structural and biological features. However, because cancer cells in different areas of the prostate may have different degrees of malignant potential, the pathologist must use the sum of scores obtained from various sections of the tissue biopsied from the prostate gland. Information about the Gleason grading system is summarized below. It is important not only for you to know about the Gleason system but also for you to discuss your Gleason score with your doctor. • The Gleason score is obtained by assigning one Gleason grade to the most dominant pattern and another to the next most common pattern. • By convention, the result is expressed as a sum, with the primary pattern listed first. • Thus, the Gleason score can range from 2 (resulting from 1 + 1) to 10 (5 + 5). • There are five patterns, or grades, of prostate cells ranging from normal, noncancerous cells to malignant cells without any glandular organization. • Prostate cancers are usually assigned Gleason grades ranging from 2 through 5, because Gleason scores of 1 are very rare. Identification and Screening for Prostate Cancer 23 Stages of Prostate Cancer Stages of Prostate Cancer Tests Used to Stage Prostate Cancer...................................24 Radionuclide Bone Scan ............................................24 MRI (Magnetic Resonance Imaging)............................25 Other Tests....................................................................26 Prostate Cancer Stages........................................................27 TNM Staging System..........................................................32 How Prostate Cancer Spreads.............................................35 Tests Used to Stage Prostate Cancer Radionuclide Bone Scan After prostate cancer has been diagnosed, tests are done to find out if cancer cells have spread, a process called staging. The information gathered from the staging process determines the stage of the disease. It is important to know the stage in order to plan treatment. This next section describes tests and procedures that may be used in the staging process. A radionuclide bone scan is performed to check if there are rapidly dividing cells, such as cancer cells, in the bone. During this procedure a very small amount of radioactive material is injected into a vein that travels through the bloodstream. The radioactive material collects in the bones and is then detected by a scanner. 24 Stages of Prostate Cancer As illustrated in Figure 7, the patient lies on a table that slides under the scanner where the radioactive material is detected and images are made on a computer screen or film. MRI (Magnetic Resonance Imaging) Figure 7. Bone scan. Photo courtesy of the National Cancer Institute. Magnetic resonance imaging (MRI) is a procedure that uses a magnet, radio waves, and a computer to make a series of detailed pictures of areas inside the body. This procedure is also called nuclear magnetic resonance imaging (NMRI). Stages of Prostate Cancer 25 Stages of Prostate Cancer Radionuclide bone scan is better than regular x-rays in detecting cancer that has spread to the bones. Most prostate cancer metastases are multiple and most commonly localized to the long bones of the skeleton. Men who undergo radionuclide bone scans generally have more advanced local lesions, symptoms of metastases (eg, bone pain), more aggressive disease, or elevations in PSA >20 ng/mL. MRI allows for evaluation of the prostate as well as regional lymph nodes; its ability to detect tissue invasion is similar to that of transrectal ultrasound. Other Tests ◗◗ PELVIC LYMPHADENECTOMY: A surgical procedure to remove the lymph nodes in the pelvis so a pathologist can view the tissue under a microscope to look for cancer cells. ◗◗ CT SCAN (CAT SCAN): A series of detailed computerlinked x-rays of areas inside the body are taken from different angles. A dye may be injected into a vein or swallowed to create a clearer contrasted image of the organs or tissues. This procedure is also known as computed tomography, computerized tomography, or computerized axial tomography. ◗◗ SEMINAL VESICLE BIOPSY: Fluid from the glands 26 Stages of Prostate Cancer that make semen, the seminal vesicles, is removed using a needle so that a pathologist can view it under a microscope and look for cancer cells. Stages of Prostate Cancer Prostate Cancer Stages As prostate cancer progresses from stage I to stage IV, the cancer cells grow within the prostate, through the outer layer of the prostate into nearby tissue, and then to lymph nodes or other parts of the body. Stage Stage I Description Illustration In stage I, cancer is found in the prostate only. The cancer tissue is found by needle biopsy (such as for a high PSA level) or in a small amount of tissue during surgery for other reasons (such as benign prostatic hyperplasia). • The PSA level is lower than 10, and the Gleason score is 6 or lower; or cancer is found in one-half or less of one lobe of the prostate. • The PSA level is lower than 10, and the Gleason score is 6 or lower; or a mass cannot be felt during a digital rectal exam and is not visible by imaging. Cancer is found in one-half or less of one lobe of the prostate. • The PSA level and the Gleason score are not known. Stages of Prostate Cancer 27 Stage Stage II Description Illustration In stage II, cancer is more advanced than in stage I, but has not spread outside the prostate. Stage II is divided into stage IIA and stage IIB. Stage IIA Stage IIA 28 Cancer is found by needle biopsy (such as for a high PSA level) or in a small amount of tissue during surgery for other reasons (such as benign prostatic hyperplasia). • The PSA level is lower than 20, and the Gleason score is 7; or cancer is found by needle biopsy (such as for a high PSA level) or in a small amount of tissue during surgery for other reasons (such as benign prostatic hyperplasia). • The PSA level is at least 10 but lower than 20, and the Gleason score is 6 or lower; or cancer is found in one-half or less of one lobe of the prostate. Stages of Prostate Cancer Stage IIB Stage Description Illustration • The PSA level is at least 10 but lower than 20, and the Gleason score is 6 or lower; or cancer is found in one-half or less of one lobe of the prostate. • The PSA level is lower than 20, and the Gleason score is 7; or cancer is found in more than one-half of one lobe of the prostate. • The PSA level is lower than 20, and the Gleason score is 7 or lower; or cancer is found in more than one-half of one lobe of the prostate. • The PSA level and the Gleason score are not known. Stage IIB Cancer is found in opposite sides of the prostate. • The PSA can be of any level, and the Gleason score can range from 2 to 10; or a mass cannot be felt during a digital rectal exam and is not visible by imaging, and the tumor has not spread outside the prostate. • The PSA level is 20 or higher, and the Gleason score can range from 2 to 10; or a mass cannot be felt during a digital rectal exam and is not visible by imaging, and the tumor has not spread outside the prostate. • The PSA can be of any level and the Gleason score is 8 or higher. Stages of Prostate Cancer Stages of Prostate Cancer Stage IIA (cont’d) 29 Stage Stage III 30 Description In stage III, cancer has spread beyond the outer layer of the prostate and may have spread to the seminal vesicles. The PSA can be of any level, and the Gleason score can range from 2 to 10. Stages of Prostate Cancer Illustration Stage Illustration In stage IV, the PSA can be of any level, and the Gleason score can range from 2 to 10. Also, cancer has spread beyond the seminal vesicles to nearby tissue or organs, such as the rectum, bladder, or pelvic wall; or may have spread to the seminal vesicles or to nearby tissue or organs, such as the rectum, bladder, or pelvic wall. Cancer has spread to nearby lymph nodes or has spread to distant parts of the body, which may include lymph nodes or bones. Prostate cancer often spreads to the bones. Stages of Prostate Cancer Stage IV Description Stages of Prostate Cancer 31 TNM Staging System TNM staging system, which stands for Tumor, Node, Metastasis, is an internationally recognized staging system developed by The American Joint Committee on Cancer. The table on the following page describes the TNM staging system in greater detail. • T refers to the size of the primary tumor • N describes the extent of regional lymph node involvement • M refers to the presence or absence of metastases In addition, the equivalent stages in the A, B, C, D, or JewettWhitmore, system are given in parentheses in the table. 32 Stages of Prostate Cancer Table 2: TNM Staging System Stage TX, T0, T1 Stage T2 T2 Palpable tumor confined to prostate TO No evidence of primary tumor T2a (B1) Tumor involves half of one prostate lobe or less T1 (A) Tumor not clinically apparent T1a (A1) Tumor incidentally found in ≤5% of prostate sample T1b (A2) Tumor incidentally found in >5% of prostate sample T1c (B0) Tumor identified at needle biopsy performed to investigate PSA elevation Stage T4 T3 (C1) Tumor palpable and extends beyond prostate capsule T3a (C1) Tumor extends beyond prostate capsule, either on one side (unilaterally) or both sides (bilaterally) T4 Tumor is fixed or invades adjacent anatomy other than seminal vesicles: bladder neck, external sphincter, rectum, elevator muscles, and/or pelvic wall T2b (B2) Tumor involves more than half of one lobe but not both lobes T2c (B2) Tumor involves both prostate lobes T3b (C2-3) Tumor invades seminal vesicles Stages of Prostate Cancer 33 Stages of Prostate Cancer TX Primary tumor cannot be assessed Stage T3 N Staging M Staging Stage NX, N0, N1 Stage MX, M0, M1 NX Regional lymph nodes cannot be assessed MO No distant metastasis NO No regional lymph node metastasis M1a Metastasis to nonregional lymph nodes N1 Metastasis in regional lymph node or nodes M1c Metastasis to other distant sites 34 Stages of Prostate Cancer M1 Distant metastasis M1b Metastasis to bone Prostate cancer can spread throughout the body: • Through tissue. Cancer invades the surrounding normal tissue. • Through the lymph system. Cancer invades the lymph system and travels through the lymph vessels to other places in the body. cancer spreads to the bones, the cancer cells in the bones are actually prostate cancer cells, not bone cancer. The disease is then called metastatic prostate cancer. When prostate cancer comes back (recurs) after it has been treated, it is called recurrent prostate cancer. The cancer may recur in the prostate or in other parts of the body. • Through the blood. Cancer invades the veins and capillaries and travels through the blood to other places in the body. Metastasis is the process of cancer cells breaking away from the primary (original) tumor and traveling through the lymph system or blood to other places in the body forming a secondary tumor. The secondary (metastatic) tumor is the same type of cancer as the primary tumor, even though it may be found in another part of the body. For example, if prostate Stages of Prostate Cancer 35 Stages of Prostate Cancer How Prostate Cancer Spreads Questions to Ask Your Doctor • What kind of tests do I need? • What does my PSA level mean? • What is the Gleason score of my prostate cancer? • What is the stage of my prostate cancer? • Has the prostate cancer spread to other areas of my body? • Should I get a second opinion? 36 Stages of Prostate Cancer Treatment of Prostate Cancer Treatment of Prostate Cancer Treatment of Prostate Cancer 37 Treatment of Prostate Cancer Overview of Treatment Options.......................................................38 Watchful Waiting or Active Surveillance........................................38 Surgery...............................................................................................38 Cryosurgery..................................................................................41 Possible Side Effects of Surgery...................................................41 More about Surgery.....................................................................41 Radiation Therapy............................................................................43 External Beam Radiation Therapy..............................................43 3-Dimensional Conformal Radiational Therapy........................44 Conformal Proton Beam Radiation Therapy..............................44 Intensity Modlated Radiation Therapy.......................................44 Possible Side Effects of Radiation Therapy.................................45 Hormone Therapy.......................................................................46 Chemotherapy...................................................................................48 Possible Side Effects....................................................................48 Biologic Therapy...............................................................................49 Possible Side Effects.....................................................................49 Clinical Trials..............................................................................49 Possible New Treatments..................................................................50 High-Intensity Focused Ultrasound............................................51 Proton Beam Radiation Therapy................................................52 Overview of Treatment Options Standard options available for patients with prostate cancer include watchful waiting or active surveillance and treatments such as surgery, radiation, hormone therapy, and chemotherapy. Standard treatments in current use are discussed below. Watchful Waiting or Active Surveillance Since it is often difficult to predict which prostate cancers will worsen or spread, and because cancer treatments usually have side effects, watchful waiting or active surveillance is an approach to consider. With this in mind, until a patient develops symptoms or until symptoms change after diagnosis of early prostate cancer, the only treatment recommended may be to closely monitor a patient’s condition. This is referred to as watchful waiting. If changes in test results occur, a patient’s condition can be observed through active surveillance to 38 Treatment of Prostate Cancer find early signs that the condition is getting worse. In active surveillance, patients are given certain exams and tests, including biopsies, on a regular schedule. Surgery The are four surgical procedures that may be recommended for patients with prostate cancer who are in good health. They include: ◗◗ PELVIC LYMPHADENECTOMY: The lymph nodes in the pelvis are surgically removed. The doctor will usually not remove the prostate if the lymph nodes contain cancer and may recommend another treatment. ◗◗ RADICAL PROSTATECTOMY: The prostate, surrounding tissue, and seminal vesicles are all surgically removed. There are 2 types of radical prostatectomy: ◗◗ Retropubic prostatectomy: The prostate is surgically removed through an incision in the abdominal wall. Removal of nearby lymph nodes may be done at the same time. Figure 8: Two types of radical prostatectomy. Retropubic is shown on the left and perineal on the right. Photo courtesy of the National Cancer Institute. Treatment of Prostate Cancer 39 Treatment of Prostate Cancer ◗◗ Perineal prostatectomy: The prostate is surgically removed through an incision in the area between the scrotum and anus. Nearby lymph nodes may also be removed through a separate incision in the abdomen. ◗◗ TRANSURETHRAL RESECTION OF THE PROSTATE (TURP): Tissue from the prostate is surgically removed using a thin, lighted tube with a cutting tool called a resectoscope that is inserted through the urethra. This procedure is sometimes done to relieve urinary symptoms caused by a tumor before other cancer treatment is given. In such a situation, the surgery is palliative—done to relieve symptoms—rather than curative. TURP may also be performed in men who cannot have a radical prostatectomy because of age or illness. Figure 9: Transurethral resection of the prostate (TURP). Tissue is removed from the prostate using a resectoscope (a thin, lighted tube with a cutting tool at the end) inserted through the urethra. Prostate tissue that is blocking the urethra is cut away and removed through the resectoscope. [Courtesy of the NCI, permission requested] 40 Treatment of Prostate Cancer Cryosurgery, or cryotherapy, uses an instrument to freeze and destroy prostate cancer cells. Inguinal hernia, a bulging of fat or part of the small intestine through weak muscles in the groin, may occur within the first 2 years after retropubic radical prostatectomy. Possible Side Effects of Surgery More about Surgery Cryosurgery Side effects of surgery can include: • Leakage of urine from the bladder; • Leakage of stool from the rectum. To help avoid impotence, doctors can use a technique known as nerve-sparing surgery. This type of surgery may save the nerves that control erection. However, men with large tumors or tumors that are very close to the nerves may not be able to have this surgery. Treatment of Prostate Cancer • Impotence; • Radical prostatectomy can last from about 1.5 to 4 hours. The perineal surgery is generally shorter than retropubic surgery. –– After these procedures, a catheter is usually inserted into the urethra to permit urination during the healing process and should be needed for a few weeks or less. –– After the catheter is removed, a patient should be able to urinate on his own. • After the prostate is removed, it is sent for evaluation of the margins, or edges, of the prostate. Treatment of Prostate Cancer 41 Questions to ask your doctor and/or surgeon • If the margins of the prostate do not have cancer cells (negative margins), it is assumed that the cancer was entirely within the prostate and has not spread. • Laparoscopic radical prostatectomy uses 4 or 5 small incisions in the abdomen. The surgeon inserts a long tube-like camera into one of the incisions to see the prostate area and places long instruments into the other incisions to remove the prostate and the nearby tissues. • Is prostate surgery an option for me? • What type of prostate surgery do you recommend? • What are the benefits of prostate surgery? • What kind of side effects are possible, and how can they be managed? • How many of these surgeries have you done? • What options do I have besides surgery? 42 Treatment of Prostate Cancer Radiation Therapy Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. Radiation therapy can be used in an attempt to cure prostate cancer or can be palliative — used to ease symptoms. The two types of radiation therapy are: External Beam Radiation Therapy • In external beam radiation therapy, a machine delivers the radiation in short sessions, usually one session for 5 days each week for 7 to 9 weeks. • Internal radiation therapy, known as brachytherapy: uses a radioactive substance sealed in needles, pellets, called “seeds”, wires, or catheters that are placed directly into or near the cancer. • As in an x-ray, the machine focuses on a specific part of the body. –– High-dose brachytherapy: Radioactive seeds are inserted into the prostate for 5 to 15 minutes and then removed. A few treatments may be given over the course of several days. Advances in external beam radiation therapy have led to three methods of treatment that are described here. These developments may help reduce side effects and increase treatment success. Treatment of Prostate Cancer • External radiation therapy: uses a machine outside the body to send radiation toward the cancer. –– Severe urinary incontinence is uncommon, but approximately one-third of men may experience frequent urination. • The treatment itself is painless and takes only a few minutes. Treatment of Prostate Cancer 43 3-Dimensional Conformal Radiation Therapy • Computers are used to identify the location of the prostate and the cancer inside the prostate gland and irradiate just that area. • The technique involves the creation of a patientdedicated protection device that is similar to a body cast, but is molded out of plastic and helps to keep the body immobile. • This permits the radioactive beam to accurately deliver a high dose of radiation to the prostate while limiting the surrounding areas’ radiation exposure. Conformal Proton Beam Radiation Therapy • Conformal proton beam radiation therapy (CPBRT) relies on a technique similar to that of 3-dimensional conformal radiation therapy, except that it uses protons to produce the radiation beam. • Unlike x-rays, which release energy both before and after they hit a cancer, protons may produce less damage to tissues through which they pass and may help to spare healthy tissue. Intensity Modulated Radiation Therapy • Intensity modulated radiation therapy (IMRT) relies on computed tomography (CT) to create a 3D picture of the prostate, with radiation delivered only to the prostate gland. • In IMRT, a computer-driven machine moves around the 44 Treatment of Prostate Cancer patient, targeting radiation to the prostate from several different angles. • The intensity of the radiation can be adjusted to reduce the dose that reaches healthy tissue while enabling a higher dose to reach the cancer. • Thus, IMRT can permit an increased radiation dose to be delivered to the prostate gland. Possible Side Effects of Radiation Therapy • Skin redness, tenderness, or sensitivity • Extreme fatigue • Inflammation inside the mouth after radiation therapy to the head and neck area. Make sure to tell your doctor if you experience any side effects. Treatment of Prostate Cancer 45 Treatment of Prostate Cancer Side effects of radiation therapy may depend on the area that is having the radiation treatment. The side effects usually lessen in time. However, sometimes they may continue for several months after treatment is finished. Your doctor may be able to provide recommendations for coping with some of the side effects. Some side effects of radiation therapy include: Questions to ask your doctor • Is radiation therapy an option for me? • How effective is radiation therapy versus prostate surgery in early stage prostate cancer? • How effective is radiation therapy for advanced prostate cancer? • What type of radiation therapy do you recommend? • What are the benefits of this type of radiation therapy? • What are the possible side effects? • What are my options besides surgery or radiation? 46 Treatment of Prostate Cancer Hormone Therapy Hormones are substances made by glands in the body and circulated in the bloodstream. During hormone therapy, hormones are removed or blocked to prevent cancer cells from growing. In prostate cancer, drugs, surgery, or other hormones are used to reduce the amount of male hormones or block them from working in order to prevent the growth of prostate cancer. The side effects of hormonal therapy vary from medication to medication and can include hot flashes, impaired sexual function, loss of desire for sex, and weakened bones. Other side effects may include diarrhea, nausea, and pruritus (itching). Be sure to mention any side effects you may experience to your doctor, who may be able to help you to manage them. Advantages and disadvantages of hormone therapy should be discussed with your doctor. Questions to ask your doctor • Is hormone therapy an option for me? • What are my hormone therapy options? • Which hormone therapy do you recommend? Do you recommend drugs or surgery? • What are the benefits of this treatment? Treatment of Prostate Cancer • What are the side effects, and how can they be managed? • If I choose hormone drug therapy, how long do I have to take these medications? • What happens if the hormone therapy stops working? Treatment of Prostate Cancer 47 Chemotherapy Possible Side Effects Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Some chemotherapy drugs are taken by mouth as pills, while others are given into a vein (intravenously) in a doctor’s office or clinic. Chemotherapy that is placed directly into the cerebrospinal fluid, an organ, or a body cavity such as the abdomen and mainly affects cancer cells in those areas is called regional chemotherapy. The way the chemotherapy is given depends on the type and stage of the cancer being treated. Every patient may experience side effects of chemotherapy differently, and severity can vary from person to person. In addition, side effects depend on which treatment is used. The most common side effects of chemotherapy can include: • Anemia (low red blood cell count) • Extreme fatigue • Hair loss • Increased risk of bruising, bleeding, and infection • Nausea and vomiting • Leukopenia (low white blood cell count) 48 Treatment of Prostate Cancer Biologic Therapy Biologic therapy, biotherapy, or immunotherapy is a treatment that uses the patient’s immune system to fight cancer. Substances made by the body or made in a laboratory are used to boost, direct, or restore the body’s natural defenses against cancer. Biological therapies may also cause side effects. What side effects occur and how severe these side effects may be depend on individual patients’ characteristics and their treatment plans. The following are some side effects that can be associated with biological therapy drugs. • When a biological therapy drug is given intravenously, the injection site can become red and sore. Serious phlebitis (vein inflammation) occasionally results. • Fatigue is a common side effect of biological therapy. • Allergic reactions may also occur including cough, wheezing, and skin rash. Clinical Trials Your doctor can help you decide whether a clinical trial is an option for you. Clinical trials, also known as research studies, are used to test a new treatment to determine if it is safe, effective, and possibly better than standard treatments. Talk to your doctor to determine if a clinical trial might be an option for you. Each clinical trial has a specific policy on what type of patients should be included and excluded. Factors such as age, gender, type of disease, prior treatments, or medical Treatment of Prostate Cancer 49 Treatment of Prostate Cancer Possible Side Effects • Flu-like symptoms may develop, including fever, chills, gastrointestinal upset, and body aches. history may determine if the patient is appropriate for a given clinical trial. In addition, every trial has specific rules and guidelines for when patients need to have tests and procedures, as well as when they will receive medications and at what doses. In addition, patients will be seen regularly by the research team to monitor and determine if the treatment is working and if the patient is experiencing any side effects. Testing of treatments occurs in phases. Most clinical trials are categorized as phase I, II, III, or IV. Phase I trials are often the first studies to test a new drug in people. • Phase I trials typically evaluate how a new drug should be given and how much of the drug may be given safely. Only a small group (20 to 80) of people may be enrolled. • Phase II trials further test the safety of the drug and 50 Treatment of Prostate Cancer begin to measure how well the drug works. A larger group (100 to 300) of patients is likely to be enrolled. • Phase III trials typically compare the safety and efficacy of the new treatment with the current standard treatment. Phase III trials often enroll a large number of patients (1000 to 3000) at different sites. • Phase IV trials are conducted after a new treatment has been approved and is available to be prescribed. These trials typically evaluate the safety and efficacy of a drug over a longer period of time in a larger number of patients. Possible New Treatments This summary section describes treatments that are being studied in clinical trials. It may not mention every new treatment being studied. High-Intensity Focused Ultrasound High-intensity focused ultrasound uses ultrasound waves to destroy cancer cells. An endorectal probe is used to make the sound waves for the treatment of prostate cancer. Proton Beam Radiation Therapy • www.cancer.gov/clinical_trials—a service of the National Cancer Institute • www.clinicaltrials.gov—a service of the US National Institutes of Health • www.cancertrialshelp.org—a service of the Coalition of Cancer Cooperative Groups Treatment of Prostate Cancer Proton beam radiation therapy is a type of high-energy, external radiation therapy that targets tumors with streams of protons. This type of radiation therapy is being studied in the treatment of prostate cancer. These Web sites provide more information about clinical research trials • www.emergingmed.com—a site that helps identify appropriate clinical trials for patients Advantages and disadvantages of any of these treatment methods should be discussed with your doctor. Treatment of Prostate Cancer 51 Questions to ask your doctor • Is a clinical trial an option for me? • What types of clinical trials are available? • What do researchers know about the medicines being studied? • What are the benefits? What are the side effects? • How long will the clinical trial last? • Do I have to see another doctor? • Are extra tests needed? • Are extra visits to the doctor required? • Will my health insurance cover the costs of the clinical trial? 52 Treatment of Prostate Cancer Treatment Options by Stage Although there are different ways that each stage of prostate cancer may be treated, the following information describes some of the most common approaches to treatment. Treatment Options by Stage Stage I Prostate Cancer.........................53 Stage II Prostate Cancer........................54 Stage III Prostate Cancer.......................54 Stage IV Prostate Cancer......................55 Recurrent Prostate Cancer....................55 Stage I Prostate Cancer Treatment of stage I prostate cancer may include the following: • Watchful waiting or active surveillance • Radical prostatectomy, usually with pelvic lymphadenectomy, with or without radiation therapy after surgery. It may be possible to remove the prostate without damaging nerves that are necessary for an erection • External-beam radiation therapy • Clinical trials Treatment Options by Stage 53 Treatment Options by Stage • Implant radiation therapy Stage II Prostate Cancer Stage III Prostate Cancer Treatment of stage II prostate cancer may include the following: Treatment of stage III prostate cancer may include the following: • Watchful waiting or active surveillance • Radical prostatectomy, with or without pelvic lymphadenectomy. Radiation therapy may be given after surgery. It may be possible to remove the prostate without damaging nerves that are necessary for an erection • External-beam radiation therapy with or without hormone therapy • Implant radiation therapy • Clinical trials • External-beam radiation therapy with or without hormone therapy • Hormone therapy • Radical prostatectomy, with or without pelvic lymphadenectomy. Radiation therapy may be given after surgery • Watchful waiting or active surveillance • Radiation therapy, hormone therapy, or transurethral resection of the prostate as palliative therapy to relieve symptoms caused by the cancer • Clinical trials 54 Treatment of Prostate Cancer Stage IV Prostate Cancer Recurrent Prostate Cancer Treatment of stage IV prostate cancer may include the following: Treatment of recurrent prostate cancer may include the following: • Hormone therapy • Radiation therapy • External-beam radiation therapy with or without hormone therapy • Prostatectomy for patients initially treated with radiation therapy • Radiation therapy or transurethral resection of the prostate as palliative therapy to relieve symptoms caused by the cancer • Hormone therapy • Watchful waiting or active surveillance • Chemotherapy • Clinical trials • Pain medicine, external radiation therapy, internal radiation therapy with radioisotopes such as strontium-89, or other treatments as palliative therapy to lessen bone pain • Clinical trials Treatment Options by Stage 55 Treatment Options by Stage Advantages and disadvantages of various types of treatment should be discussed with your doctor. • Biologic therapy with sipuleucel-T for patients already treated with hormone therapy Prognosis Prognosis Factors Affecting Prognosis.................................................56 Survival by Stage.................................................................56 Treatment Follow-up and Monitoring................................57 Localized or Locally Advanced Prostate Cancer................57 Advanced Prostate Cancer..................................................58 Factors Affecting Prognosis Certain factors affect prognosis (chance of recovery) and treatment options, including the following: • The stage of the cancer (whether it affects part of the prostate, involves the whole prostate, or has spread to other places in the body). • The patient’s age and health. • Whether the cancer has just been diagnosed or has recurred (come back). • The Gleason score and the level of PSA. 56 Prognosis Survival by Stage The survival statistics shown in Table 3 are based on what is called “relative survival.” This is a measure of survival of cancer patients in comparison to the general population. The overall 5-year relative survival for 2002–2008 from multiple geographic areas was 99.2%. Five-year relative survival by race was: 99.6% for white men; 96.2% for black men. Prognosis Table 3: 5-year Relative Survival by Stage Treatment Follow-up and Monitoring Percentage of Patients per Stage (%) 5-year Relative Survival (%) Localized (confined to primary site) 81 100.0 Regional (spread to regional lymph nodes) 12 100.0 • Patients must be monitored at regular intervals according to a long-term follow-up plan. Distant (cancer has metastasized) 4 27.8 • During and after treatment, PSA tests can help to determine a patient’s status and whether further testing may be required. Unknown (unstaged) 3 71.1 Stage at Diagnosis Localized or Locally Advanced Prostate Cancer After initial treatment for prostate cancer has been completed, risk of recurrence is the principal concern. • It is not possible to determine which patients are likely to have a recurrence. Prognosis 57 Guidelines recommend that post-treatment PSA levels be checked every 6 to 12 months for the first 5 years after treatment and then yearly thereafter. Advanced Prostate Cancer Follow-up for advanced prostate cancer is similar to that of earlier stages. • An increase or change in the PSA level does not necessarily signal a recurrence • Follow-up visits for patients on hormone therapy will involve injections and/or prescription refills • Additional tests to determine whether prostate cancer has recurred include: • Patients will be monitored for side effects from hormone therapy –– Biopsy –– Bone scan –– CT or MRI • Annual DRE is also recommended because prostate cancer can recur without a change in PSA level 58 Prognosis Prognosis Questions Frequently Asked by Patients • What is the risk of my prostate cancer returning or getting worse? • What type of follow-up and monitoring do you recommend? • What is a typical PSA level for a person who has received the treatment I have received? • What happens if my PSA level starts to rise? • Do I need to change treatments if my PSA does not decrease? • What other tests will I need? Prognosis 59 Living with Prostate Cancer Living with Prostate Cancer Keep a Positive Outlook.......................................................................60 How Should I Feel?...............................................................................60 Take Action...........................................................................................61 What’s the Best Way to Cope with My Diagnosis?..............................62 How Will Prostate Cancer Affect My Relationships?..........................62 How Much Should I Tell My Partner?..................................................62 Keep a Positive Outlook How Should I Feel? Prostate cancer may raise feelings that you may find hard to deal with. Take advantage of all the help you can find, especially from your family and friends, as well as your health care team. Tell them what you are thinking and what you need. There are many ways that men deal with having prostate cancer, and every man is entitled to his own feelings. Learning that you or a loved one has prostate cancer may give rise to concerns and emotions that you may find difficult to confront. It’s natural to be worried about treatment, side effects, the future, and how prostate cancer may affect you and your loved ones. Each person has his or her own way of dealing with concerns and emotions; there is no right or wrong way to handle them. Many sources of support and comfort are available to you, including your family, friends, and health care team. If you need to find a support group or other resources to help you, call the American Cancer Society at 1-800-ACS-2345. 60 Living with Prostate Cancer After receiving a diagnosis of prostate cancer, many men feel a range of emotions such as fear and anger. Many men also have questions and want to know what they can do to take an active role in their care. There are several ways that you can become more active in making decisions about your care. For example, you can: • Learn about the disease. Educational materials are available on the Internet as well as from your doctor. Living with Prostate Cancer Take Action • Find out about the treatment options currently available and talk to your doctor about which ones may be appropriate for you. • Talk to your doctor and health care providers. You should feel comfortable asking them questions and, if you want to, getting a second opinion. If you change doctors after your initial treatment, make sure your new doctor has a complete set of records from your previous doctor and hospital. • Join a support group. You can find valuable information and resources by talking to others who are going through the same thing. Living with Prostate Cancer 61 What’s the Best Way to Cope with My Diagnosis? How Will Prostate Cancer Affect My Relationships? Being informed and in charge may help you feel more in control and relieve some fears. Become a partner with your health care team—your urologist, radiation oncologist, medical oncologist, nurse, technician, and counselor. Ask questions about your condition. Find out about the risks, benefits, and side effects of your treatment options, and how the treatment you choose will affect your life. It’s a good idea to write down all of your questions and answers so you can refer to the information later. Once you have decided on a treatment option, follow the advice from your health care team and let them know about any new symptoms or other concerns you may have. Talk about your illness with your family and close friends. Some people may shy away at first because they want to help you but don’t know how. If you are honest about what you need, this may help you maintain relationships that will support you. 62 Living with Prostate Cancer How Much Should I Tell My Partner? The more your partner understands and shares in your care, the more your partner can give you support. Your partner can help you cope with and manage your illness if you include her or him; for example, your partner can go with you to doctor visits and help you go over treatment options. You may want to talk to a professional counselor if you have concerns about intimacy with your partner. Additional Information About Prostate Cancer Additional Information About Prostate Cancer From the National Cancer Institute.........................63 Support Groups and Resources.................................64 From the National Cancer Institute For more information from the National Cancer Institute about prostate cancer, see the following: http://www.cancer.gov/cancertopics/types/prostate What You Need to Know About™ Prostate Cancer http://www.cancer.gov/cancertopics/wyntk/prostate Prostate Cancer Prevention http://www.cancer.gov/cancertopics/pdq/prevention/prostate/Patient Prostate Cancer Screening http://www.cancer.gov/cancertopics/pdq/screening/prostate/Patient Drugs Approved for Prostate Cancer http://www.cancer.gov/cancertopics/druginfo/prostatecancer Prostate-Specific Antigen (PSA) Test http://www.cancer.gov/cancertopics/factsheet/Detection/PSA Treatment Choices for Men with Early-Stage Prostate Cancer http://www.cancer.gov/cancertopics/treatment/prostate/ understanding-prostate-cancer-treatment/ Cryosurgery in Cancer Treatment: Questions and Answers http://www.cancer.gov/cancertopics/factsheet/Therapy/cryosurgery Additional Information About Prostate Cancer Additional Information About Prostate Cancer Prostate Cancer Home Page 63 Support Groups and Resources American Cancer Society (ACS) The following list of resources is provided as a convenience to you. AstraZeneca takes no responsibility for the content of, or services provided by, these resources and makes no representation as to the accuracy or completeness of any information provided by these resources. AstraZeneca shall have no liability for any damages or injuries of any kind arising from the information provided by the resources listed. The descriptions of the organizations are all directly from their respective Web sites. 250 Williams Street NW, Suite 600 Atlanta, GA 30303 1-800-ACS-2345 (1-800-227-2345) www.cancer.org 64 Additional Information About Prostate Cancer The American Cancer Society is the largest volunteer organization in the United States and is committed to saving lives from cancer by helping people stay well, helping people get well, by finding cures and fighting back. There are 900 local offices nationwide to deliver lifesaving programs and services at the community level. CancerCare 1000 Corporate Boulevard Linthicum, MD 21090 410-689-3990 1-800-828-7866 275 Seventh Avenue Floor 22 New York, NY 10001 212-712-8400 1-800-813-HOPE (1-800-813-4673) www.cancercare.org www.urologyhealth.org The AUA Foundation is the nation’s leading urologic health charity that promotes research, education, and advocacy. AUA Foundation’s mission is to improve prevention, detection, and treatment of urologic diseases. CancerCare is a national nonprofit organization that provides free professional support services to anyone affected by cancer: people with cancer, caregivers, children, loved ones, and the bereaved. CancerCare programs — including counseling, education, financial assistance, and practical help—are provided by trained oncology social workers and are completely free of charge. Founded in 1944, CancerCare provided individual help to more than 100,000 people in 2009. Additional Information About Prostate Cancer 65 Additional Information About Prostate Cancer American Urological Association Foundation (AUAF) Men’s Health Network (MHN) Prostate Cancer Foundation (PCF) Men’s Health Network PO Box 75972 Washington, DC 20013 202-543-MHN-1 (202-543-6461) www.menshealthnetwork.org 1250 Fourth Street Santa Monica, CA 90401 310-570-4700 1-800-757-CURE (1-800-757-2873) www.prostatecancerfoundation.org The Men’s Health Network provides information about disease prevention, screening programs, and disease education materials for a number of diseases affecting men’s health. The Men’s Health Network, which currently has a board of advisors including more than 800 physicians and key thought leaders, was founded in 1992 by a group of health professionals and others interested in improving the health and well-being of men, boys, and families. The Prostate Cancer Foundation (PCF) is the world’s largest philanthropic source of support for prostate cancer research to fund better treatments and a cure for prostate cancer. PCF pursues its mission by soliciting and selecting promising research programs and rapid deployment of resources. Founded in 1993, the PCF has raised more than $370 million and has provided funding for more than 1,500 research projects at nearly 200 institutions worldwide. 66 Additional Information About Prostate Cancer Prostate Conditions Education Council (PCEC) The Prostate Net 7009 South Potomac Street, Suite 125 Centennial, CO 80112 303-316-4685 1-866-477-6788 www.prostateconditions.org PO Box 2192 Secaucus, NJ 07096-2192 Phone: 1-888-477-6763 www.theprostatenet.org Additional Information About Prostate Cancer Additional Information About Prostate Cancer The Prostate Conditions Education Council provides information on prostate health. The Council, founded in 1989, is made up of a consortium of leading physicians, health educators, scientists, and prostate cancer advocates. The aim of the Council is to provide information, conduct nationwide screenings for men, and perform research that will aid in the detection and treatment of prostate and men’s health conditions. The Prostate Net develops and maintains an interactive network of educational tools and services for consumers. These services are offered to educate, inform, and motivate consumers to make informed choices about prostate cancer and other prostate diseases. 67 Us TOO International Prostate Cancer ZERO – The Project to End Prostate Cancer Education & Support Network 5003 Fairview Avenue Downers Grove, IL 60515 630-795-1002 1-800-80-UsTOO (1-800-808-7866) www.ustoo.org 10 G Street NE, Suite 601 Washington, DC 20002 202-463-9455 1-888-245-9455 www.zerocancer.org 68 Additional Information About Prostate Cancer ZERO – The Project to End Prostate Cancer is committed to reducing prostate cancer, alleviating the pain from the disease, and ultimately to end it. To accomplish these goals, ZERO provides comprehensive treatment information to patients, education to those at risk, and conducts free prostate cancer testing throughout the country. They work to increase research funds from the federal government and fund research in the pursuit of a better test for this disease. Glossary The following is a list of some medical terms that you may not know. A ACTIVE SURVEILLANCE: also called watchful waiting or expectant management; it is the decision not to treat the prostate cancer immediately with surgery, radiation, hormone therapy, or any other treatment options. Instead, the doctor monitors the patient’s prostate cancer by checking the PSA level and looking for signs and symptoms of cancer growth/ progression. A decision to start therapy can be made later if the cancer gets worse. ADRENAL GLANDS: two small triangle-shaped glands located on the top of each kidney that make various hormones, including androgens. ANDROGEN: any hormone that causes male physical characteristics (for example, facial hair or a deep voice). The main androgen is testosterone. ANESTHESIA: a drug administered for medical or surgical purposes that causes partial or total loss of sensation with or without loss of consciousness. ANTIANDROGEN: drugs that fight prostate cancer by blocking the effects of testosterone; can be used in combination with orchiectomy. ANUS: the opening at the lower end of the rectum. B BENIGN: noncancerous tumor that doesn’t spread and is usually not life-threatening. BENIGN PROSTATIC HYPERPLASIA (BPH): noncancerous enlargement of the prostate caused by an overgrowth of the cells in the prostate. Glossary Glossary 69 BIOPSY: a small piece of tissue that is removed from the body and examined under a microscope for the presence of cancer. BLINDED: a study design in which patients (and sometimes their physicians) do not know which therapy or medication is being given. BRACHYTHERAPY: a procedure in which tiny seeds made up of radioactive material are placed directly into the prostate [see INTERSTITIAL RADIATION THERAPY]. C CANCER: a term for diseases in which abnormal cells grow and divide without control and possibly spread to other parts of the body. CASTRATION: treatment that stops or lowers testosterone production by testicles. Castration is done surgically (orchiectomy) or medically (using an LHRH analog and antagonist). 70 Glossary CASTRATION-RESISTANT PROSTATE CANCER: a term used to describe prostate cancer in which the cancer gets worse despite a very low level of testosterone (as a result of hormone therapy or orchiectomy). CATHETER: a tube that is temporarily put through the urethra into the bladder to take out urine or to empty the bladder. CELLS: the basic units of the body that give it structure and make it function. CHEMOTHERAPY: drugs that move throughout the body in the bloodstream and may kill any rapidly growing cells, including cancer cells and some healthy cells. CLINICAL TRIALS: research studies in patients with cancer or other diseases, usually for a new or investigational drug or treatment. These studies help answer questions about a new therapy, or they can look at new ways of using an existing therapy. COMBINED ANDROGEN BLOCKADE (CAB): hormone therapy to treat prostate cancer that combines an antiandrogen drug with an LHRH analog or an orchiectomy. Also called maximum androgen blockade or total androgen blockade. ERECTION: enlargement of the penis due to increased blood flow. EXTERNAL BEAM RADIATION THERAPY: therapy from machines outside the body that aim radiation beams at the prostate to destroy cancer cells. CRYOSURGERY: see CRYOTHERAPY. CRYOTHERAPY: also called cryosurgery; repeated freezing and thawing of the tumor cells causing cell death. D DIGITAL RECTAL EXAMINATION (DRE): an examination done by a doctor using a gloved lubricated finger, which is inserted into the rectum to check for lumps, enlargements, or areas of hardness in the prostate that might suggest the patient has prostate disease or an abnormality. E HORMONE THERAPY: in prostate cancer, treatment that affects how much male hormone the body makes or that blocks the action of male hormones that can feed or fuel prostate cancer. I IMPOTENCE: not being able to have an erection. IMMUNE CELL: a type of blood cell that fights infections. IMMUNOTHERAPY: therapy that uses the body’s immune system to help fight diseases. Glossary 71 Glossary EJACULATION: act or process of sudden or spontaneous discharging of sperm and seminal fluid from the penis. H INTERSTITIAL RADIATION THERAPY: treatment with high-energy radiation from tiny radioactive seeds inserted into the prostate [see BRACHYTHERAPY]. LUTEINIZING HORMONE-RELEASING HORMONE (LHRH) analogs: drugs that treat prostate cancer by stopping the testicles from making testosterone. INVESTIGATIONAL THERAPY: treatment or drug being tested in clinical research trials for a particular disease or condition. LYMPH: a usually clear fluid from tissues in the body that is returned to the blood by the lymphatic system. Lymph plays an important role in the immune system and helps carry waste away from cells. L LYMPH NODES: small, bean-shaped structures scattered along the vessels of the lymphatic system. The lymph nodes filter out or remove waste, bacteria, and cancer cells that may travel through the lymphatic system. LAPAROSCOPIC RADICAL PROSTATECTOMY: a type of surgery to remove the prostate and nearby tissues that uses four or five small incisions in the abdomen and a camera to see the prostate. LAPAROSCOPIC SURGERY: surgery that inserts a small camera (laparoscope) into the body through a small surgical incision, enabling the physician to view internal organs. LHRH ANTAGONISTS: drugs that treat prostate cancer by interfering with the physiological action of luteinizing hormone-releasing hormone. 72 Glossary LYMPHADENECTOMY: surgical removal of lymph nodes. LYMPHATIC SYSTEM: a network of vessels, nodes, ducts, and organs that help regulate the body’s fluid environment and protect the body by making lymph. Vessels or tubes that carry lymph are part of this system. Other parts include lymph nodes and several organs throughout the body that make and store cells that fight infections. M O MALIGNANCY: a cancerous tumor that can grow and spread and may be life-threatening. ORCHIECTOMY: the surgical removal of the testicles (testes), the main source of male hormones. It is also called SURGICAL CASTRATION. MEDICAL CASTRATION: the use of drugs to reduce the level of testosterone to levels similar to those seen after orchiectomy. MEDICAL ONCOLOGIST: a doctor trained in internal medicine who has specialized training in how to diagnose and treat patients with cancer. METASTATIC: referring to the spread of cancer from the original tumor to other parts of the body. N NERVE-SPARING RADICAL RETROPUBIC PROSTATECTOMY: surgical removal of the prostate through an incision in the lower abdomen, in which the nerves on either side of the prostate are saved, if possible. P PATHOLOGIST: a doctor who specializes in the diagnosis of disease by studying cells and tissues with a microscope. PERINEUM: the area between the scrotum and the anus. PLACEBO: a treatment or substance that is not active but looks similar to, and is given in a similar manner to, an active drug. Glossary Glossary PLACEBO-CONTROLLED CLINICAL TRIAL: a study in which a group of patients (control group) is given a placebo instead of the new therapy or drug being investigated. To determine if the new therapy or drug works, this control group is then compared with the group of patients that was given the new therapy or drug. 73 PROSTATE-SPECIFIC ANTIGEN (PSA): a substance in the blood made by both normal and cancerous prostate cells. The PSA level often increases in patients with prostate cancer and other prostate diseases. PROSTATITIS: inflammation of the prostate. PSA DOUBLING TIME (PSA-DT): the time it takes for a PSA value to double. R RADIATION THERAPY: treatment for cancer that uses radiation to kill cancer cells and shrink tumors. RADICAL PERINEAL PROSTATECTOMY: surgery to remove the prostate through an incision in the perineum. RADICAL PROSTATECTOMY: an operation to remove the entire prostate gland, seminal vesicles, and some of the surrounding tissue. 74 Glossary RADICAL RETROPUBIC PROSTATECTOMY: surgery to remove the prostate through an incision in the lower abdomen. RANDOMIZED: study design in which patients are assigned randomly (by chance) to individual groups that assess different therapies, without knowing at the time of the study which therapy is best. This random assignment allows fair comparison of the different treatments. RECTUM: the last 5 or 6 inches of the large intestine leading to the anus. S SCROTUM: the external sac, or pouch, of skin containing the testicles. SEMEN: the fluid that is ejaculated during sexual climax; it contains the sperm and fluids from other glands, including the prostate. SEMINAL VESICLES: pouches above the prostate that store semen. SPERM: mature male sex cell. SPINAL CORD COMPRESSION: growth of cancer cells in or near the spine, pressing on the spinal cord and nerves. This can cause symptoms such as back pain, numbness, dizziness, problems urinating, and constipation or other bowel problems. STAGE: the size and extent to which the cancer may have grown and spread. T TESTICLES (TESTES): male reproductive glands that make the sperm and testosterone. TESTOSTERONE: a male sex hormone made mostly by the testicles, responsible for the sexual characteristics of men. TRANSRECTAL ULTRASONOGRAPHY (TRUS): a procedure in which a special probe is inserted in the rectum and sound waves are used to produce an image of the prostate and the surrounding organs so that the prostate gland can be evaluated. TRANSURETHRAL RESECTION OF THE PROSTATE (TURP): surgery to remove extra tissue from the prostate with a special instrument that is inserted through the urethra. TUMOR: an abnormal mass of cells, resulting from cells that divide and grow in an uncontrolled and disorderly way. Tumors may be cancerous (malignant) or noncancerous (benign). U URETERS: the tubes that carry urine from each kidney (one ureter per kidney) to the urinary bladder. Glossary TISSUE: a group of cells specially made/organized to do a particular function in the body. Glossary 75 URETHRA: the tube that carries urine from the urinary bladder and semen from the sex glands to the outside of the body. URINARY BLADDER: the hollow organ that stores urine. URINARY INCONTINENCE: not being able to control the flow of urine from the bladder. UROLOGIST: a doctor who specializes in diseases of the urinary and sex organs in males and the urinary organs in females. 76 Glossary 1709608-Understanding Breast Cancer Guide Book. AstraZeneca. 8/12. References References American Cancer Society. Radiation therapy. Available at: http://www.cancer.org/Cancer/ProstateCancer/ DetailedGuide/prostate-cancer-treating-radiation-therapy. Accessed June 2, 2011. American Cancer Society. Early Detection Diagnosis and Staging. Available at: http://www.cancer.org/Cancer/ ProstateCancer/DetailedGuide/prostate-cancer-detection. Accessed June 1, 2011. American Cancer Society. Surgery for prostate cancer. Available at: http://www.cancer.org/Cancer/ProstateCancer/ DetailedGuide/prostate-cancer-treating-surgery. Accessed June 2, 2011. American Cancer Society. Hormone (Androgen Deprivation) therapy. Available at: http://www.cancer.org/ Cancer/ProstateCancer/DetailedGuide/prostate-cancertreating-hormone-therapy. Accessed June 1, 2011. American Joint Committee on Cancer. Cancer Staging Manual. 7th ed. Springer Publisher, New York 10013. American Cancer Society. How is Prostate Cancer Staged? Available at: http://www.cancer.org/cancer/prostatecancer/ detailedguide/prostate-cancer-staging. Accessed September 13,2012. Cancer.net. American Society Clinical Oncology. Prostate Cancer – Risk Factors and Preventions. Accessed on Sept 6, 2012. MD Anderson Manual of Medical Oncology, Chapter 34, Prostate Cancer. McGraw-Hill Publishers, New York, 2012. References 77 Meng MV. Prostate Cancer, Chapter 39 in Current Medical Dx & Tx, McGraw-Hill Publishers, New York, 2012. Morton DA, Foreman KB, Albertine KH. Male reproductive system, Chapter 13 in The Big Picture: Gross Anatomy, McGraw-Hill Publishers, New York, 2011. National Cancer Institute at the National Institutes of Health. General Information About Prostate Cancer. Available at: http://www.cancer.gov/cancertopics/pdq/ treatment/prostate/Patient. Accessed June 5, 2011. National Cancer Institute at the National Institutes of Health. Prostate cancer treatment overview. Available at: http://www.cancer.gov/cancertopics/pdq/treatment/prostate/ Patient/page4. Accessed June 3, 2011. National Cancer Institute at the National Institutes of Health. Prostate-Specific Antigen (PSA) Test. Available at: http://www.cancer.gov/cancertopics/factsheet/detection/PSA. Accessed September 3, 2012. 78 References National Cancer Institute at the National Institutes of Health. SEER Stat Fact Sheets: Prostate. Available at: http://seer.cancer.gov/statfacts/html/prost.html. Accessed September 13, 2012. NCCN Clinical Practice Guidelines in Oncology™. Prostate Cancer Early Detection. Standring S. Prostate, Chapter 75 in Gray’s Anatomy 40th Edition, Churchill Livingstone Elsevier, Philadelphia 2008. Provided as an educational service by AstraZeneca. If you have any questions about your condition, talk to your doctor. Models used for illustrative purposes only. 2012 Astrazeneca Pharmaceuticals LP. All rights reserved. 2071401 10/12
© Copyright 2024